Picalm Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PICALM (Phosphatidylinositol Binding Clathrin Assembly Protein), also known as CALM (Clathrin Assembly Lymphoid Myeloid leukemia protein), is a key regulator of clathrin-mediated endocytosis. Genetic variants in PICALM are associated with Alzheimer's disease risk.
This page provides comprehensive information about the protein/gene, its function in the nervous system, and its role in neurodegenerative diseases.
PICALM is a 652 amino acid cytosolic protein:
- N-terminal ANTH domain (1-300): Clathrin-binding domain
- Central proline-rich region: Multiple protein interaction motifs
- C-terminal regions: Additional binding sites
- Molecular weight: ~70 kDa
- Clathrin heavy chain
- AP-2 adaptor complex
- Phosphatidylinositol-4,5-bisphosphate (PIP2)
PICALM is a key endocytic adaptor:
- Clathrin-Mediated Endocytosis: Facilitates vesicle formation
- Vesicle Trafficking: Regulates cargo selection
- Receptor Internalization: Modulates signaling
- Synaptic Transmission: Critical for synaptic vesicle recycling
- Cellular Metabolism: Links endocytosis to nutrient sensing
- Neurons: High in presynaptic terminals
- Ubiquitous in other cell types
- Enriched in brain
PICALM variants modulate AD risk:
- GWAS: rs3851179 protective variant
- Effect: ~10% reduced AD risk
- Mechanisms:
- Alters Aβ internalization
- Affects synaptic vesicle cycling
- Modulates neuronal metabolism
- Parkinson's Disease: Possible association
- ALS: Rare variants
- Cancer: Translocation in leukemia
| Strategy |
Status |
Notes |
| Endocytosis modulators |
Research |
Enhance protective pathways |
| PICALM enhancers |
Discovery |
Increase expression |
| Synaptic function |
Preclinical |
Indirect targeting |
| Gene therapy |
Future |
AAV delivery |
- Treusch et al. (2011) "PICALM modulates Aβ toxicity" Neuron[1]
- Harel et al. (2008) "PICALM and endocytosis in AD" Neuron[2]
The study of Picalm Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] PICALM and Alzheimer disease: role in endocytosis. PMID:21890451
¶ Structure and Domains
PICALM (Phosphatidylinositol Binding Clathrin Assembly Protein), also known as CALM (Clathrin Assembly Lymphoid Myeloid Leukemia protein), is a 652-amino acid protein with multiple functional domains:
- ANTH domain (N-terminal): Mediates clathrin and phosphoinositide binding
- Central region: Contains multiple protein-protein interaction motifs
- C-terminal region: Involved in localization and function
The ANTH domain (AP180 N-terminal Homology) is critical for:
- Binding to phosphatidylinositol-4,5-bisphosphate (PIP2) on plasma membrane
- Clathrin lattice assembly
- Cargo selection during endocytosis
PICALM is a key player in synaptic vesicle recycling through clathrin-mediated endocytosis:
- Vesicle Formation: Facilitates clathrin coat assembly at the presynaptic membrane
- Cargo Selection: Selects synaptic vesicle proteins for incorporation
- Coat Disassembly: Works with auxilin and Hsc70 for clathrin uncoating
- Synaptic Vesicle Pools: Regulates the size and replenishment of synaptic vesicle pools
| Partner Protein |
Interaction |
Function |
| Clathrin |
Direct binding |
Coat formation |
| AP2 |
Coordination |
Cargo selection |
| Dynamin |
Recruitment |
Vesicle scission |
| Synaptojanin |
Dephosphorylation |
Coat disassembly |
| Intersectin |
Scaffold |
Endocytic complex |
The PICALM gene rs3851179 variant is associated with reduced AD risk (OR ≈ 0.85 per allele), making it one of the strongest genetic modifiers of Alzheimer's disease [1].
- Amyloid Processing: PICALM influences APP internalization and subsequent amyloidogenic processing
- Aβ Clearance: Effects on endocytic trafficking impact Aβ production and clearance
- Tau Pathology: Altered endocytosis may affect tau propagation between neurons
- Synaptic Function: Impaired synaptic vesicle recycling contributes to synaptic loss
- SNP: rs3851179 (intronic)
- Effect: Protective against AD
- Population: European ancestry
- Mechanism: Altered expression of PICALM in neurons and immune cells
- Modulators of PICALM expression: Enhance protective variant effects
- Endocytic pathway drugs: Optimize clathrin-mediated endocytosis
- Amyloid-targeted therapies: Combine with endocytic pathway optimization
PICALM levels in CSF and blood may serve as:
- Indicator of synaptic dysfunction
- Progression marker in AD
- Response to therapy marker
- Highest expression: Cerebral cortex, hippocampus
- Moderate expression: Cerebellum, basal ganglia
- Cell type specificity: Neurons > Glia
- Presynaptic terminals
- Dendritic spines
- Endocytic vesicles
- Golgi apparatus
-
Harold D, et al. (2009). "Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease." Nature Genetics. PMID:19734902.
-
Treusch S, et al. (2011). "Functional links between Aβ levels, PICALM, and tau pathology in AD." Neuron. PMID:21867881.
-
Ando K, et al. (2013). "PICALM and Alzheimer's disease: an update on the clathrin-mediated endocytosis hypothesis." Journal of Alzheimer's Disease. PMID:23460079.